drugset

drugset / Trial / NCT04733833

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19

NCT04733833 ↗

Phase 2 Completed 5 enrolled Vascular Biogenics Ltd. operating as VBL Therapeutics

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this Phase 2 study is to test safety, efficacy, and tolerability of an oral preparation of VB-201 in patients with severe COVID-19

Timeline

Start: 2021-01-26
Primary completion: 2022-10-25
Completion: 2022-10-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VB-201	Small molecule	80 mg	Oral

Indications